WisdomTree BioRevolution

Details

ETF description

The WisdomTree BioRevolution ETF provides investors with exposure to companies at the forefront of the biotechnology and life sciences sectors, focusing on innovations driving the future of healthcare. By tracking the WisdomTree BioRevolution index, this ETF includes firms involved in genomic research, gene editing, biotechnology advancements, and other transformative areas within the life sciences industry. The ETF aims to capitalize on the growth potential of companies pioneering breakthroughs in medicine and biotechnology. It is designed for investors seeking to invest in cutting‑edge biotechnology and healthcare innovations with the potential for significant long‑term growth and advancement in the field.

Issuer details

WisdomTree is a leading asset management firm specializing in innovative ETFs and ETPs (exchange‑traded products), with over $80 billion in assets under management as of June 2024. WisdomTree offers an extensive range of investment products across various market segments. Founded in 2006, WisdomTree is known for its fundamentally weighted ETFs and its focus on providing innovative and thematic investment strategies. The firm places a strong emphasis on income‑focused products, catering to the needs of income‑seeking investors. Notable ETFs include the WisdomTree U.S. Quality Dividend Growth Fund (DGRW), the WisdomTree Europe Hedged Equity Fund (HEDJ), and the WisdomTree Cloud Computing Fund (WCLD), reflecting WisdomTree’s commitment to delivering diverse and forward‑looking investment solutions.

Index details

The BioRevolution index provides focused exposure to companies at the forefront of biotechnological innovation and advancements in life sciences. By emphasizing firms involved in biotechnology, genetic research, and related fields, this index aims to capture growth opportunities within the rapidly evolving sector. Its focus on cutting‑edge biotechnological and life sciences companies makes it a valuable addition for portfolios seeking to invest in transformative advancements and long‑term growth potential within the bio‑revolution.